Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

KANSAS CITY, Kan., Sept. 18, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced the full exercise of the underwriters' option to purchase 675,000 additional shares of common stock in connection with the company's previously announced public offering of 4,500,000 shares of common stock.  All of the shares are being offered by Aratana Therapeutics.  With the exercise of the underwriters' option, net proceeds to Aratana from the offering are expected to be approximately $44.8 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Aratana Therapeutics.

Jefferies LLC and Barclays are acting as joint book-running managers for the offering. 

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on July 15, 2014, which became effective on July 30, 2014.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A prospectus supplement describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from Jefferies LLC, c/o Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd FL, New York, NY 10022,, (877) 547-6340; or Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department,, (888) 603-5847.

For investor inquires:
Aratana Therapeutics, Inc.

Craig Tooman; (913) 353-1023

For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.

print email rss